Literature DB >> 12818755

[Recombinant Human Erythropoietin (r-HuEPO) therapy in a newborn with hereditary spherocytosis].

M Schiff1, S Haÿs, L Sann, G Putet.   

Abstract

UNLABELLED: The newborn with hereditary spherocytosis can develop severe anemia, requiring red blood cell transfusions. Therapy with r-HuEPO has been proposed to avoid transfusions. CASE REPORT: Hereditary spherocytosis was diagnosed in a newborn who had severe and early jaundice. He was treated with r-HuEPO, and did not require red blood cells transfusion.
CONCLUSION: Recombinant erythropoïetin might be an interesting alternative to red blood cells transfusions during the neonatal period in newborns with hereditary spherocytosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818755     DOI: 10.1016/s0929-693x(03)00043-5

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

Review 1.  A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates.

Authors:  Robert D Christensen; Hassan M Yaish; Patrick G Gallagher
Journal:  Pediatrics       Date:  2015-06       Impact factor: 7.124

2.  The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience.

Authors:  Jacqueline F Morrison; Ellis J Neufeld; Rachael F Grace
Journal:  Eur J Haematol       Date:  2014-04-16       Impact factor: 2.997

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.